胃癌分子靶向治疗研究新进展

被引：28

作者：

黎军和

熊建萍

机构：

[1] 南昌大学第一附属医院肿瘤科

来源：

中国肿瘤临床 | 2015年 / 42卷 / 23期

关键词：

胃癌; 胃食管连接部腺癌; 靶点; 靶向治疗;

D O I：

暂无

中图分类号：

R735.2 [胃肿瘤];

学科分类号：

100112 [医学生物化学与分子生物学];

摘要：

进展期胃癌及胃食管连接部(gastroesophageal junction,GEJ)腺癌的预后差。与最佳支持治疗相比,化疗能够延长患者生存期,改善生存质量,但单纯化疗患者中位生存期(median survival)仅为7～10个月。近年随着对胃癌发病分子机制的深入了解,多种靶向关键信号传导途径的分子靶向治疗药物进行了国际多中心临床研究,改变了胃癌的治疗模式。To GA研究显示靶向HER-2(human epidermal growth factor receptor 2,HER-2)的单克隆抗体曲妥珠单抗联合化疗可使HER-2阳性的进展期胃癌患者OS达13.8个月。此外,多项靶向胃癌血管生成、c-Met、PARP、免疫治疗的临床研究正在进行中,本文对近年胃癌及GEJ腺癌分子靶向治疗的研究现状进行综述。

引用

页码：1118 / 1123

页数：6

共 11 条

[1]

Anti program death-1/anti program death-ligand 1 in digestive cancers [J].

de Guillebon, Eleonore ;

Roussille, Pauline ;

Frouin, Eric ;

Tougeron, David .

WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2015, 7 (08) :95-101

[2]

Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer [J].

Bang, Yung-Jue ;

Im, Seock-Ah ;

Lee, Keun-Wook ;

Cho, Jae Yong ;

Song, Eun-Kee ;

Lee, Kyung Hee ;

Kim, Yeul Hong ;

Park, Joon Oh ;

Chun, Hoo Geun ;

Zang, Dae Young ;

Fielding, Anitra ;

Rowbottom, Jacqui ;

Hodgson, Darren ;

O'Connor, Mark J. ;

Yin, Xiaolu ;

Kim, Woo Ho .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (33) :3858-+

[3]

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial [J].

Wilke, Hansjochen ;

Muro, Kei ;

Van Cutsem, Eric ;

Oh, Sang-Cheul ;

Bodoky, Gyoergy ;

Shimada, Yasuhiro ;

Hironaka, Shuichi ;

Sugimoto, Naotoshi ;

Lipatov, Oleg ;

Kim, Tae-You ;

Cunningham, David ;

Rougier, Philippe ;

Komatsu, Yoshito ;

Ajani, Jaffer ;

Emig, Michael ;

Carlesi, Roberto ;

Ferry, David ;

Chandrawansa, Kumari ;

Schwartz, Jonathan D. ;

Ohtsu, Atsushi .

LANCET ONCOLOGY, 2014, 15 (11) :1224-1235

[4]

Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review) [J].

Shimoyama, Shouji .

MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (02) :175-181

[5]

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial [J].

Fuchs, Charles S. ;

Tomasek, Jiri ;

Yong, Cho Jae ;

Dumitru, Filip ;

Passalacqua, Rodolfo ;

Goswami, Chanchal ;

Safran, Howard ;

dos Santos, Lucas Vieira ;

Aprile, Giuseppe ;

Ferry, David R. ;

Melichar, Bohuslav ;

Tehfe, Mustapha ;

Topuzov, Eldar ;

Zalcberg, John Raymond ;

Chau, Ian ;

Campbell, William ;

Sivanandan, Choondal ;

Pikiel, Joanna ;

Koshiji, Minori ;

Hsu, Yanzhi ;

Liepa, Astra M. ;

Gao, Ling ;

Schwartz, Jonathan D. ;

Tabernero, Josep .

LANCET, 2014, 383 (9911) :31-39

[6]

HER2-positive gastric cancer [J].

Boku, Narikazu .

GASTRIC CANCER, 2014, 17 (01) :1-12

[7]

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial [J].

Waddell, Tom ;

Chau, Ian ;

Cunningham, David ;

Gonzalez, David ;

Frances, Alicia ;

Okines, Clare ;

Wotherspoon, Andrew ;

Saffery, Claire ;

Middleton, Gary ;

Wadsley, Jonathan ;

Ferry, David ;

Mansoor, Wasat ;

Crosby, Tom ;

Coxon, Fareeda ;

Smith, David ;

Waters, Justin ;

Iveson, Timothy ;

Falk, Stephen ;

Slater, Sarah ;

Peckitt, Clare ;

Barbachano, Yolanda .

LANCET ONCOLOGY, 2013, 14 (06) :481-489

[8]

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial [J].

Lordick, Florian ;

Kang, Yoon-Koo ;

Chung, Hyun-Cheol ;

Salman, Pamela ;

Oh, Sang Cheul ;

Bodoky, Gyoergy ;

Kurteva, Galina ;

Volovat, Constantin ;

Moiseyenko, Vladimir M. ;

Gorbunova, Vera ;

Park, Joon Oh ;

Sawaki, Akira ;

Celik, Ilhan ;

Goette, Heiko ;

Melezinkova, Helena ;

Moehler, Markus .

LANCET ONCOLOGY, 2013, 14 (06) :490-499

[9]

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial [J].

Van Cutsem, Eric ;

de Haas, Sanne ;

Kang, Yoon-Koo ;

Ohtsu, Atsushi ;

Tebbutt, Niall C. ;

Xu, Jian Ming ;

Yong, Wei Peng ;

Langer, Bernd ;

Delmar, Paul ;

Scherer, Stefan J. ;

Shah, Manish A. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2119-2127

[10]

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [J].

Bang, Yung-Jue ;

Van Cutsem, Eric ;

Feyereislova, Andrea ;

Chung, Hyun C. ;

Shen, Lin ;

Sawaki, Akira ;

Lordick, Florian ;

Ohtsu, Atsushi ;

Omuro, Yasushi ;

Satoh, Taroh ;

Aprile, Giuseppe ;

Kulikov, Evgeny ;

Hill, Julie ;

Lehle, Michaela ;

Ruschoff, Josef ;

Kang, Yoon-Koo .

LANCET, 2010, 376 (9742) :687-697

← 1 2 →